Kimberly Blackwell Board Member May 2022. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company's products include ZN-c5 and ZN-c3. - Zentalis Pharmaceuticals Peter Huang, PhD Senior Vice President, Discovery Research Zentalis provides an inspiring work environment for both young scientists and biotech veterans. The average twelve-month price prediction for Zentalis Pharmaceuticals is $74.43 with a high price target of $120.00 and a low price target of $51.00.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Zentalis Pharmaceuticals Inc. said it selling 954,000 common shares at $26.21 a share to Pfizer Inc. for proceeds of $25 million. Zentalis Pharmaceuticals has 2 board members and advisors, including Kimberly Blackwell. Ongoing Clinical Trials AllZN-c3ZN-d5ZN-c5ZN-e4 ZN-c3 Phase 2 Uterine Serous Carcinoma Study Phase 2 Biomarker-Driven Study Phase 1/2 Solid Tumors Study
June 1, 2022. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 .
Not so for Zentalis Pharmaceuticals, which priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March. It also means that they are potentially on the cusp .
By Chris Wack.
Candidate Name Cand. Following the sale, the chief operating officer now directly owns 110,000 shares in the company, valued at $3,307,700. Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, is a majority shareholder of Shanghai, China-based Zentera. Company Description: Zentalis Pharmaceuticals, Inc. is located in New York, NY, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. A high-level overview of Zentalis Pharmaceuticals, Inc. (ZNTL) stock. Zentalis Pharmaceuticals.
Five research analysts have rated the stock with a buy recommendation. ZN-c5 is an oral selective estrogen receptor degrader, which is in a Phase I/II clinical trial for .
General Information: Business: We are a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers .
Zentalis Pharmaceuticals Inc. said it selling 954,000 common shares at $26.21 a share to Pfizer Inc. for proceeds of $25 million. It was founded 2014 and headquartered in New York, United States. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers.
Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year. Zentalis Pharmaceuticals is a New York City and San Diego based biotech company dedicated to the discovery and development of clinically differentiated small molecules targeting fundamental biological pathways of cancer. Print. NEW YORK, April 20, 2021 /PRNewswire/ -- Empire State Realty Trust, Inc. (NYSE: ESRT) announced today that Zentalis Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on the . Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Issuer's principal executive offices are located at 1359 Broadway, Suite 1710, New York, New York 10018. Read More News; Pipeline.
The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 . The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 . Carmela Graci-Pipitone Clinical Study Manager, clinical operations at Zentalis Pharmaceuticals New York, New York, United States 164 connections Jobs Salaries Interviews. October 01, 2020 Executive Employment Agreements.
Zentalis Pharmaceuticals press release (ZNTL): Q4 GAAP EPS of -$1.11 beats by $0.22.As of December 31, 2021, cash, cash equivalents and marketable securities of $339.9M Proceeds from the Series A financing will be used to develop and commercialize three cancer . Zentalis Pharmaceuticals ( NASDAQ: ZNTL) intends to raise $130 million from an IPO of its common stock, according to an amended S-1/A registration statement.
Before joining ZNTL, Blackwell was chief .
Instead, they specialize in dealing with treatments on the molecular level that are specifically designed to combat cancer. This makes Zentalis Pharmaceuticals the world's 4057th most valuable company by market cap according to our data. Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Cam is a cofounder and President at Zentalis Pharmaceuticals and has served as a member of the Board of Directors since the Company's founding.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. According to the issued ratings of 6 analysts in the last year, the consensus rating for Zentalis Pharmaceuticals stock is Buy based on the current 6 buy ratings for ZNTL.
Developing small molecule therapeutics targeting fundamental biological pathways of cancers | Developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer Risk and Volatility. The biopharmaceutical company said the common shares were offered . Clinical-stage biotech Zentalis Pharmaceuticals ( NASDAQ: ZNTL) on Monday appointed board member Kimberly Blackwell as its CEO, replacing Anthony Sun. Our lead product candidate, ZN-c3, is a potentially first-in-class and best-in-class oral Wee1 inhibitor in development for the treatment of advanced solid tumors.
1-212-433-3791 info@zentalis.com As of June 2022 Zentalis Pharmaceuticals has a market cap of $1.23 Billion . Lists Featuring This Company City of New York Companies (Top 10K) The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 . For More Information. Zentalis Pharmaceuticals | 11,010 followers on LinkedIn. Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) shares, rose in value on Friday, 05/13/22, with the stock price up by 8.39% to the previous day's close as strong demand from buyers drove the stock to $20.53. Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Enoch Kariuki Board Member Feb 2021. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock's existing status and the future performance. Zentalis Pharmaceuticals, Inc. has 124 total employees across all of its locations. Zentalis Pharmaceuticals Company Profile . What does that mean for you, the investor? | June 18, 2022
Here's Why Zentalis Pharmaceuticals, Inc. (ZNTL) is Poised for a Turnaround After Losing 50% in 4 Weeks The heavy selling pressure might have exhausted for Zentalis Pharmaceuticals, Inc. (ZNTL) as it is technically in oversold territory now. Science Center. To learn more about our ongoing clinical trials, please visit www.clinicaltrials.gov.
Unsolicited resumes sent to Zentalis from . This statement on Schedule 13D (the " Schedule 13D ") relates to the Common Stock, par value $0.001 per share (the " Common Stock "), of Zentalis Pharmaceuticals, Inc., a Delaware corporation (the " Issuer "). The President, Anthony Sun, made the biggest insider sale in the last 12 months. Zentalis is a biopharmaceutical company.
Jobs Salaries Interviews. Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Rating) COO Kevin D. Bunker sold 25,000 shares of the stock in a transaction dated Tuesday, July 5th.
By Chris Wack. Sector: Health Care Industry: Biotechnology. There are 4 companies in the Zentalis Pharmaceuticals, Inc. corporate family. Zentalis Pharmaceuticals, Inc.: Bunker Kevin D. (Chief Operating Officer) Sells 25,000 @ Avg Price: $30.07 (Form4) Zentalis Pharmaceuticals is conducting clinical studies evaluating its small molecule therapeutics. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 .
1359 Broadway Suite 1710 New York, NY 10018 United States zentalis.com. Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Investors/Media Home Company Profile. Premium Investing Services. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The average 12 month price objective among brokerages that have issued a report . Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.
Zentalis Pharmaceuticals Company Profile .
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Carmela Graci-Pipitone Clinical Study Manager, clinical operations at Zentalis Pharmaceuticals New York, New York, United States 164 connections Zentalis Pharmaceuticals Inc., a clinical-stage cancer treatment developer, rose 29% in its trading debut after raising about $165 million in an initial public offering. Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers . Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical . That single transaction was for US$1.6m worth of . Legal Analyst Career. Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Rating) has been assigned an average rating of "Buy" from the seven brokerages that are presently covering the stock, Marketbeat reports.
As a collective team, Zentalis employees contribute different perspectives while supporting one other in the effort to bring innovative treatments to cancer patients. May 31, 2022. Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers.
Comparatively, Zentalis Pharmaceuticals has a beta of 2.74 . The Human Resources team manages the recruitment and employment process for Zentalis Pharmaceuticals, Inc. (Zentalis) To protect the interest of all parties involved, Zentalis will only accept resumes from a recruiter if an executed search agreement is in place at the start of the recruitment effort. Popular Careers with Zentalis Job Seekers. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers . The biopharmaceutical company said the common . Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid .
There are 4 companies in the Zentalis Pharmaceuticals, Inc. corporate family. It focuses on developing clinically differentiated and small molecule therapeutics. Zentalis Pharmaceuticals is not your typical pharmaceutical company.
The company is advancing a pipeline of . Vertex Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Zentalis pulls off speedy $165M IPO amid pandemic-driven . The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective . Zentalis Pharmaceuticals, Inc. has 124 total employees across all of its locations. Jobs Salaries Interviews. Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary. 10835 Road to the Cure Suite 205 San Diego, CA 92121. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to . Jobs Salaries Interviews. The proxy statement for the 2022 Annual Meeting of Stockholders (the "Proxy Statement") of Zentalis Pharmaceuticals, Inc., a Delaware corporation (the "Company"), to be held on June 8, 2022 (the "Meeting"), was filed with the Securities and Exchange Commission on April 28, 2022.Since then, there have been developments regarding the management of the Company. Zentalis Pharmaceuticals, Inc. Chief Operating Officer employment agreement. Zentalis Pharmaceuticals to Participate in the Jefferies Healthcare Conference. Company Description: Zentalis Pharmaceuticals, Inc. is located in New York, NY, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.
Developing small molecule therapeutics targeting fundamental biological pathways of cancers | Developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.
The company aims to address major unmet medical needs for patients with cancer. Zentalis Pharmaceuticals, LLC. Zentalis Pharmaceuticals | 11,010 followers on LinkedIn. Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. 10275 Science Center Drive Suite 200 San Diego, CA 92121 Item 1. We use our highly efficient drug discovery engine, which we refer to as our Integrated Discovery Engine, to . Actively observing the price movement in the last trading, the stock closed the session at $18.94, falling within a range of $18.63 and $21.48. NEW YORK and SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small. Medical Writer Career. About Zentalis .
On June 21, 2022, Alexis M. Pinto notified Zentalis Pharmaceuticals, Inc. (the "Company") of her resignation as Chief Legal Officer and Secretary of the Company, effective as of July 5, 2022. Zentalis Pharmaceuticals Inc. (ZNTL) full year performance was -55.68%. Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways in cancer. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.
Zentalis Pharmaceuticals, Inc. annual reports of executive compensation and pay are most commonly found in the Def 14a documents. In addition to Zentalis, Cam currently serves on the Board of . Senior Clinical Research Associate Career. Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Zentalis Pharmaceuticals Insider Transactions Over The Last Year. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Zentalis Pharmaceuticals Inc. shares rose 16% to $23.89 after the company said Kimberly Blackwell will succeed Anthony Sun as chief executive. Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 and ZN-c5 and Two Potentially Registrational Trials for ZN-c3, with the. Executive Assistant Career. Presently, Zentalis Pharmaceuticals Inc. shares are logging -71.61% during the 52-week period from high price . The stock was sold at an average price of $30.07, for a total transaction of $751,750.00. Show more Healthcare biotech drug development healthtech pharma View Jobs (16) Recent News All News Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical . He has 30 years of experience in the life sciences, with a focus on corporate development, marketing and company formation, and financing. It means that they are dealing with a very specific niche.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Zentalis Pharmaceuticals Inc. said it selling 954,000 common shares at $26.21 a share to Pfizer Inc. for proceeds of $25 million. Zentalis Pharmaceuticals has 2 board members and advisors, including Kimberly Blackwell. Ongoing Clinical Trials AllZN-c3ZN-d5ZN-c5ZN-e4 ZN-c3 Phase 2 Uterine Serous Carcinoma Study Phase 2 Biomarker-Driven Study Phase 1/2 Solid Tumors Study
June 1, 2022. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 .
Not so for Zentalis Pharmaceuticals, which priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March. It also means that they are potentially on the cusp .
By Chris Wack.
Candidate Name Cand. Following the sale, the chief operating officer now directly owns 110,000 shares in the company, valued at $3,307,700. Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, is a majority shareholder of Shanghai, China-based Zentera. Company Description: Zentalis Pharmaceuticals, Inc. is located in New York, NY, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. A high-level overview of Zentalis Pharmaceuticals, Inc. (ZNTL) stock. Zentalis Pharmaceuticals.
Five research analysts have rated the stock with a buy recommendation. ZN-c5 is an oral selective estrogen receptor degrader, which is in a Phase I/II clinical trial for .
General Information: Business: We are a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers .
Zentalis Pharmaceuticals Inc. said it selling 954,000 common shares at $26.21 a share to Pfizer Inc. for proceeds of $25 million. It was founded 2014 and headquartered in New York, United States. Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers.
Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year. Zentalis Pharmaceuticals is a New York City and San Diego based biotech company dedicated to the discovery and development of clinically differentiated small molecules targeting fundamental biological pathways of cancer. Print. NEW YORK, April 20, 2021 /PRNewswire/ -- Empire State Realty Trust, Inc. (NYSE: ESRT) announced today that Zentalis Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on the . Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Issuer's principal executive offices are located at 1359 Broadway, Suite 1710, New York, New York 10018. Read More News; Pipeline.
The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 . The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 . Carmela Graci-Pipitone Clinical Study Manager, clinical operations at Zentalis Pharmaceuticals New York, New York, United States 164 connections Jobs Salaries Interviews. October 01, 2020 Executive Employment Agreements.
Zentalis Pharmaceuticals press release (ZNTL): Q4 GAAP EPS of -$1.11 beats by $0.22.As of December 31, 2021, cash, cash equivalents and marketable securities of $339.9M Proceeds from the Series A financing will be used to develop and commercialize three cancer . Zentalis Pharmaceuticals ( NASDAQ: ZNTL) intends to raise $130 million from an IPO of its common stock, according to an amended S-1/A registration statement.
Before joining ZNTL, Blackwell was chief .
Instead, they specialize in dealing with treatments on the molecular level that are specifically designed to combat cancer. This makes Zentalis Pharmaceuticals the world's 4057th most valuable company by market cap according to our data. Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Cam is a cofounder and President at Zentalis Pharmaceuticals and has served as a member of the Board of Directors since the Company's founding.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. According to the issued ratings of 6 analysts in the last year, the consensus rating for Zentalis Pharmaceuticals stock is Buy based on the current 6 buy ratings for ZNTL.
Developing small molecule therapeutics targeting fundamental biological pathways of cancers | Developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer Risk and Volatility. The biopharmaceutical company said the common shares were offered . Clinical-stage biotech Zentalis Pharmaceuticals ( NASDAQ: ZNTL) on Monday appointed board member Kimberly Blackwell as its CEO, replacing Anthony Sun. Our lead product candidate, ZN-c3, is a potentially first-in-class and best-in-class oral Wee1 inhibitor in development for the treatment of advanced solid tumors.
1-212-433-3791 info@zentalis.com As of June 2022 Zentalis Pharmaceuticals has a market cap of $1.23 Billion . Lists Featuring This Company City of New York Companies (Top 10K) The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 . For More Information. Zentalis Pharmaceuticals | 11,010 followers on LinkedIn. Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) shares, rose in value on Friday, 05/13/22, with the stock price up by 8.39% to the previous day's close as strong demand from buyers drove the stock to $20.53. Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Enoch Kariuki Board Member Feb 2021. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock's existing status and the future performance. Zentalis Pharmaceuticals, Inc. has 124 total employees across all of its locations. Zentalis Pharmaceuticals Company Profile . What does that mean for you, the investor? | June 18, 2022
Here's Why Zentalis Pharmaceuticals, Inc. (ZNTL) is Poised for a Turnaround After Losing 50% in 4 Weeks The heavy selling pressure might have exhausted for Zentalis Pharmaceuticals, Inc. (ZNTL) as it is technically in oversold territory now. Science Center. To learn more about our ongoing clinical trials, please visit www.clinicaltrials.gov.
Unsolicited resumes sent to Zentalis from . This statement on Schedule 13D (the " Schedule 13D ") relates to the Common Stock, par value $0.001 per share (the " Common Stock "), of Zentalis Pharmaceuticals, Inc., a Delaware corporation (the " Issuer "). The President, Anthony Sun, made the biggest insider sale in the last 12 months. Zentalis is a biopharmaceutical company.
Jobs Salaries Interviews. Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Rating) COO Kevin D. Bunker sold 25,000 shares of the stock in a transaction dated Tuesday, July 5th.
By Chris Wack. Sector: Health Care Industry: Biotechnology. There are 4 companies in the Zentalis Pharmaceuticals, Inc. corporate family. Zentalis Pharmaceuticals, Inc.: Bunker Kevin D. (Chief Operating Officer) Sells 25,000 @ Avg Price: $30.07 (Form4) Zentalis Pharmaceuticals is conducting clinical studies evaluating its small molecule therapeutics. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a Wee1 .
1359 Broadway Suite 1710 New York, NY 10018 United States zentalis.com. Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Investors/Media Home Company Profile. Premium Investing Services. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The average 12 month price objective among brokerages that have issued a report . Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.
Zentalis Pharmaceuticals Company Profile .
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Carmela Graci-Pipitone Clinical Study Manager, clinical operations at Zentalis Pharmaceuticals New York, New York, United States 164 connections Zentalis Pharmaceuticals Inc., a clinical-stage cancer treatment developer, rose 29% in its trading debut after raising about $165 million in an initial public offering. Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers . Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical . That single transaction was for US$1.6m worth of . Legal Analyst Career. Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Rating) has been assigned an average rating of "Buy" from the seven brokerages that are presently covering the stock, Marketbeat reports.
As a collective team, Zentalis employees contribute different perspectives while supporting one other in the effort to bring innovative treatments to cancer patients. May 31, 2022. Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers.
Comparatively, Zentalis Pharmaceuticals has a beta of 2.74 . The Human Resources team manages the recruitment and employment process for Zentalis Pharmaceuticals, Inc. (Zentalis) To protect the interest of all parties involved, Zentalis will only accept resumes from a recruiter if an executed search agreement is in place at the start of the recruitment effort. Popular Careers with Zentalis Job Seekers. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers . The biopharmaceutical company said the common . Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid .
There are 4 companies in the Zentalis Pharmaceuticals, Inc. corporate family. It focuses on developing clinically differentiated and small molecule therapeutics. Zentalis Pharmaceuticals is not your typical pharmaceutical company.
The company is advancing a pipeline of . Vertex Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Zentalis pulls off speedy $165M IPO amid pandemic-driven . The Company is developing a broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective . Zentalis Pharmaceuticals, Inc. has 124 total employees across all of its locations. Jobs Salaries Interviews. Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary. 10835 Road to the Cure Suite 205 San Diego, CA 92121. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to . Jobs Salaries Interviews. The proxy statement for the 2022 Annual Meeting of Stockholders (the "Proxy Statement") of Zentalis Pharmaceuticals, Inc., a Delaware corporation (the "Company"), to be held on June 8, 2022 (the "Meeting"), was filed with the Securities and Exchange Commission on April 28, 2022.Since then, there have been developments regarding the management of the Company. Zentalis Pharmaceuticals, Inc. Chief Operating Officer employment agreement. Zentalis Pharmaceuticals to Participate in the Jefferies Healthcare Conference. Company Description: Zentalis Pharmaceuticals, Inc. is located in New York, NY, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.
Developing small molecule therapeutics targeting fundamental biological pathways of cancers | Developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.
The company aims to address major unmet medical needs for patients with cancer. Zentalis Pharmaceuticals, LLC. Zentalis Pharmaceuticals | 11,010 followers on LinkedIn. Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. 10275 Science Center Drive Suite 200 San Diego, CA 92121 Item 1. We use our highly efficient drug discovery engine, which we refer to as our Integrated Discovery Engine, to . Actively observing the price movement in the last trading, the stock closed the session at $18.94, falling within a range of $18.63 and $21.48. NEW YORK and SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small. Medical Writer Career. About Zentalis .
On June 21, 2022, Alexis M. Pinto notified Zentalis Pharmaceuticals, Inc. (the "Company") of her resignation as Chief Legal Officer and Secretary of the Company, effective as of July 5, 2022. Zentalis Pharmaceuticals Inc. (ZNTL) full year performance was -55.68%. Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental biological pathways in cancer. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers.
Zentalis Pharmaceuticals, Inc. annual reports of executive compensation and pay are most commonly found in the Def 14a documents. In addition to Zentalis, Cam currently serves on the Board of . Senior Clinical Research Associate Career. Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Zentalis Pharmaceuticals Insider Transactions Over The Last Year. Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Zentalis Pharmaceuticals Inc. shares rose 16% to $23.89 after the company said Kimberly Blackwell will succeed Anthony Sun as chief executive. Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 and ZN-c5 and Two Potentially Registrational Trials for ZN-c3, with the. Executive Assistant Career. Presently, Zentalis Pharmaceuticals Inc. shares are logging -71.61% during the 52-week period from high price . The stock was sold at an average price of $30.07, for a total transaction of $751,750.00. Show more Healthcare biotech drug development healthtech pharma View Jobs (16) Recent News All News Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical . He has 30 years of experience in the life sciences, with a focus on corporate development, marketing and company formation, and financing. It means that they are dealing with a very specific niche.